Aeglea BioTherapeutics, Inc. (AGLE): history, ownership, mission, how it works & makes money

A Brief History of Aeglea BioTherapeutics, Inc. (AGLE)

Company Overview

Aeglea BioTherapeutics, Inc. was founded in 2013 and is focused on developing protein therapeutics for rare metabolic diseases.

The company is based in Austin, Texas, and has specialized in the development of therapies targeting the metabolic disorder known as Arginase Deficiency.

Initial Funding and IPO

In 2014, Aeglea raised approximately $25 million in Series A funding.

In 2016, the company went public, trading on the NASDAQ under the ticker symbol AGLE.

The initial public offering (IPO) raised about $70 million for the company.

Key Product Development

Aeglea’s lead product candidate is AEB4104, designed for the treatment of Arginase Deficiency.

In 2018, Aeglea reported positive results from a Phase 1/2 clinical trial of AEB4104, demonstrating safety and efficacy.

Financial Performance

As of the most recent financial report, Aeglea reported total assets of approximately $52.5 million in 2022.

The company reported a net loss of $24 million for the year ended December 31, 2022.

Recent Developments

In 2021, Aeglea entered a strategic collaboration with a leading biopharmaceutical company to bolster research and development efforts.

Aeglea announced plans to expand its product pipeline by targeting other rare diseases in 2022.

Market Position and Future Prospects

The global market for rare disease treatments is projected to reach approximately $300 billion by 2025.

Aeglea aims to capitalize on this growing market, focusing on innovative therapies for underserved patient populations.

Regulatory Milestones

Aeglea received orphan drug designation from the FDA for AEB4104 in 2016.

The company is actively pursuing further regulatory approvals to expedite the development of its therapies.

A Who Owns Aeglea BioTherapeutics, Inc. (AGLE)

Shareholder Ownership

As of the latest update, Aeglea BioTherapeutics, Inc. (AGLE) has a diverse shareholder base comprising institutional investors and individual shareholders. The ownership structure is as follows:

Top Institutional Shareholders

The following are the leading institutional shareholders of Aeglea BioTherapeutics, along with their respective ownership stakes:

Insider Ownership

The executive team and board members also hold a significant stake in Aeglea BioTherapeutics:

Recent Financial Performance

Aeglea BioTherapeutics' stock performance and market capitalization are crucial indicators of ownership dynamics:

• Current Stock Price: $5.25
• Market Capitalization: $55 million
• 52-Week Range: $3.50 - $7.80

Conclusion of Ownership Structure

The ownership structure of Aeglea BioTherapeutics reflects a balanced mix of institutional and retail investors, emphasizing the company's appeal in the biotechnology sector.

Aeglea BioTherapeutics, Inc. (AGLE) Mission Statement

Aeglea BioTherapeutics, Inc. is dedicated to providing innovative therapies for patients with inborn errors of metabolism. The company's mission is to develop enzyme replacement therapies to improve patient quality of life and to address unmet medical needs.

Core Values

• Patient-Centricity: Prioritizing patient needs in drug development.
• Innovation: Commitment to scientific advancements in biotherapeutics.
• Integrity: Upholding ethical practices in all operations.
• Teamwork: Fostering a collaborative environment for shared success.

Strategic Goals

Aeglea aims to enhance its pipeline of therapeutic candidates, focusing on:

• Advancing Development: Progressing lead programs into clinical trials.
• Regulatory Approvals: Navigating regulatory pathways to secure approvals.
• Market Expansion: Expanding reach into new geographical markets.

Financial Overview

As of the most recent financial report for Q3 2023, Aeglea's financial highlights include:

Pipeline Overview

Aeglea has a robust pipeline focusing on rare metabolic diseases, including:

Market Opportunity

The global market for enzyme replacement therapy is projected to grow significantly, with estimations showing a market value of:

• 2023 Market Size: $10 billion
• Projected Growth Rate: 8% CAGR through 2030

Commitment to Research and Development

Aeglea allocates a substantial part of its budget to research and development:

Collaborations and Partnerships

Aeglea BioTherapeutics has established various strategic partnerships to bolster its capabilities:

• Partner with: Academic institutions for research initiatives.
• Collaborate with: Pharmaceutical companies for co-development strategies.
• Engage with: Regulatory bodies to streamline approval processes.

Future Outlook

The future outlook for Aeglea focuses on:

• Expanding Clinical Trials: More comprehensive studies to validate efficacy.
• Increasing Awareness: Boosting efforts to educate about rare diseases.
• Enhancing Accessibility: Ensuring therapies are available to those in need.

How Aeglea BioTherapeutics, Inc. (AGLE) Works

Company Overview

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) is a biotechnology company focusing on developing innovative human enzyme therapeutics to treat rare metabolic diseases. As of October 2023, Aeglea's market capitalization stands at approximately $44.1 million.

Therapeutic Focus

The primary focus of Aeglea BioTherapeutics is on the development of therapeutics for conditions such as arginase deficiency, a rare genetic disorder. The company’s lead product candidate is AEG35156, designed to reduce levels of arginine in patients with this deficiency.

Development Pipeline

Aeglea BioTherapeutics has a diverse pipeline aimed at addressing multiple metabolic disorders. The following table presents the current status of Aeglea's development pipeline:

Financial Overview

As of the latest financial reports in Q3 2023, Aeglea BioTherapeutics has reported the following financial metrics:

Stock Performance

Aeglea BioTherapeutics' stock performance has shown considerable volatility. Below is a summary of AGLE's stock performance metrics:

Collaborations and Partnerships

Aeglea has established strategic partnerships to enhance its research capabilities and expand its market reach. Current collaborations include:

• Partnership with the University of California, San Diego for advanced research on metabolic diseases.
• Collaboration with various patient advocacy groups to increase awareness for rare metabolic disorders.
• Joint research initiatives with pharmaceutical companies to explore combination therapies.

Regulatory Pathways

Aeglea BioTherapeutics actively engages with regulatory agencies to expedite the approval process for its therapies. Key approvals include:

• Fast Track Designation from the FDA for AEG35156.
• Orphan Drug Designation for AEG40826.
• Ongoing discussions with European Medicines Agency (EMA) for potential approvals in Europe.

Clinical Trials

The company is committed to advancing its clinical trial initiatives. As of Q3 2023, the following details highlight the current clinical trial status:

Future Outlook

Aeglea BioTherapeutics aims to leverage its pipeline and partnerships to address unmet medical needs in rare diseases. Upcoming milestones include:

• Data from AEG35156 Phase 2 trial expected in Q4 2023.
• Initiation of AEG40826 Phase 1 trial in Q1 2024.
• Continued exploration of new indications for AEG18743 in 2025.

How Aeglea BioTherapeutics, Inc. (AGLE) Makes Money

Revenue Sources

Aeglea BioTherapeutics, Inc. operates primarily in the biotechnology sector, focusing on the development and commercialization of therapeutics for rare diseases. The company's revenue is derived from a combination of research and development activities, collaborations, licensing agreements, and potential product sales.

Research and Development

As of Q2 2023, Aeglea reported R&D expenses of approximately $9.1 million for the quarter. This investment supports the development of their lead product candidate, AGLE-177, which targets the metabolic disorder, Argininemia.

Collaborations and Licensing Agreements

Aeglea has entered into collaboration agreements that help fund its research initiatives. For example, in 2022, they secured a partnership with a leading pharmaceutical company, generating $5 million in upfront payment, along with potential milestone payments and royalties.

Product Sales

While AGLE-177 is still in clinical trials, Aeglea anticipates that upon successful commercialization, the potential market size for Argininemia treatments is estimated at $1 billion annually. Sales projections will heavily depend on the outcomes of clinical trials and regulatory approvals.

Financial Position

As of the end of Q2 2023, Aeglea reported total assets of approximately $50 million, with cash and cash equivalents of around $25 million, which they utilize to fund ongoing operations and development.

Operating Expenses

For the first half of 2023, total operating expenses were recorded at $17 million, with administrative expenses accounting for about $7 million and R&D expenses at $10 million.

Funding and Investment

Aeglea has raised capital through equity offerings. In May 2023, the company completed a public offering, generating approximately $15 million to support ongoing clinical trials and operational costs.

Future Outlook

Projected growth is contingent on successful clinical outcomes. The company is targeting a market entry for AGLE-177 by 2024, with expectations of revenue generation in the range of $50 million in the first year post-approval, increasing to $200 million in subsequent years as they expand their therapeutic offerings.